Sustained Viremia Suppression by SHIVSF162P3CN-recalled Effector-memory CD8+ T Cells After PD1-based Vaccination

Overview

Journal PLoS Pathog

Specialty Microbiology

Date 2021 Jun 14

PMID 34125864

Citations 1

Authors

Yik Chun Wong

Wan Liu

Lok Yan Yim

Xin Li

Hui Wang

Ming Yue

Mengyue Niu

Lin Cheng

Lijun Ling

Yanhua Du

Samantha M Y Chen

Ka-Wai Cheung

Haibo Wang

Xian Tang

Jiansong Tang

Haoji Zhang

Youqiang Song

Lisa A Chakrabarti

Zhiwei Chen

Affiliations

Soon will be listed here.

Abstract

HIV-1 functional cure requires sustained viral suppression without antiretroviral therapy. While effector-memory CD8+ T lymphocytes are essential for viremia control, few vaccines elicit such cellular immunity that could be potently recalled upon viral infection. Here, we investigated a program death-1 (PD1)-based vaccine by fusion of simian immunodeficiency virus capsid antigen to soluble PD1. Homologous vaccinations suppressed setpoint viremia to undetectable levels in vaccinated macaques following a high-dose intravenous challenge by the pathogenic SHIVSF162P3CN. Poly-functional effector-memory CD8+ T cells were not only induced after vaccination, but were also recalled upon viral challenge for viremia control as determined by CD8 depletion. Vaccine-induced effector memory CD8+ subsets displayed high cytotoxicity-related genes by single-cell analysis. Vaccinees with sustained viremia suppression for over two years responded to boost vaccination without viral rebound. These results demonstrated that PD1-based vaccine-induced effector-memory CD8+ T cells were recalled by AIDS virus infection, providing a potential immunotherapy for functional cure.

Citing Articles

Enhanced Cross-Reactive and Polyfunctional Effector-Memory T Cell Responses by ICVAX-a Human PD1-Based Bivalent HIV-1 Gag-p41 Mosaic DNA Vaccine.

Chen S, Wong Y, Yim L, Zhang H, Wang H, Lui G J Virol. 2022; 96(7):e0216121.

PMID: 35297660 PMC: 9006887. DOI: 10.1128/jvi.02161-21.

References

Sun C, Chen Z, Tang X, Zhang Y, Feng L, Du Y . Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys. J Virol. 2013; 87(10):5669-77. PMC: 3648167. DOI: 10.1128/JVI.03247-12. View

Karimi M, Cao T, Baker J, Verneris M, Soares L, Negrin R . Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol. 2005; 175(12):7819-28. DOI: 10.4049/jimmunol.175.12.7819. View

Lu X, Liu L, Zhang X, Lau T, Tsui S, Kang Y . F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis. Antimicrob Agents Chemother. 2011; 56(1):341-51. PMC: 3256034. DOI: 10.1128/AAC.05537-11. View

Tewari K, Flynn B, Boscardin S, Kastenmueller K, Salazar A, Anderson C . Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates. Vaccine. 2010; 28(45):7256-66. PMC: 3004225. DOI: 10.1016/j.vaccine.2010.08.098. View

Haghverdi L, Lun A, Morgan M, Marioni J . Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors. Nat Biotechnol. 2018; 36(5):421-427. PMC: 6152897. DOI: 10.1038/nbt.4091. View

Harouse J, Gettie A, Tan R, Blanchard J, Cheng-Mayer C . Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science. 1999; 284(5415):816-9. DOI: 10.1126/science.284.5415.816. View

Yant L, Friedrich T, Johnson R, May G, Maness N, Enz A . The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol. 2006; 80(10):5074-7. PMC: 1472056. DOI: 10.1128/JVI.80.10.5074-5077.2006. View

Barouch D, Stephenson K, Borducchi E, Smith K, Stanley K, McNally A . Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 2013; 155(3):531-9. PMC: 3846288. DOI: 10.1016/j.cell.2013.09.061. View

Koup R, Safrit J, Cao Y, Andrews C, McLeod G, Borkowsky W . Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994; 68(7):4650-5. PMC: 236393. DOI: 10.1128/JVI.68.7.4650-4655.1994. View

10.

Barouch D, Tomaka F, Wegmann F, Stieh D, Alter G, Robb M . Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018; 392(10143):232-243. PMC: 6192527. DOI: 10.1016/S0140-6736(18)31364-3. View

11.

Muhl T, Krawczak M, Haaft P, Hunsmann G, Sauermann U . MHC class I alleles influence set-point viral load and survival time in simian immunodeficiency virus-infected rhesus monkeys. J Immunol. 2002; 169(6):3438-46. DOI: 10.4049/jimmunol.169.6.3438. View

12.

Liu W, Wong Y, Chen S, Tang J, Wang H, Cheung A . DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses. Vaccine. 2018; 36(31):4621-4632. DOI: 10.1016/j.vaccine.2018.06.047. View

13.

Katlama C, Deeks S, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C . Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet. 2013; 381(9883):2109-17. PMC: 3815451. DOI: 10.1016/S0140-6736(13)60104-X. View

14.

Hansen S, Sacha J, Hughes C, Ford J, Burwitz B, Scholz I . Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science. 2013; 340(6135):1237874. PMC: 3816976. DOI: 10.1126/science.1237874. View

15.

Borrow P, Lewicki H, Hahn B, Shaw G, Oldstone M . Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994; 68(9):6103-10. PMC: 237022. DOI: 10.1128/JVI.68.9.6103-6110.1994. View

16.

Liu J, OBrien K, Lynch D, Simmons N, La Porte A, Riggs A . Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature. 2008; 457(7225):87-91. PMC: 2614452. DOI: 10.1038/nature07469. View

17.

Zhou J, Cheung A, Tan Z, Wang H, Yu W, Du Y . PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice. J Clin Invest. 2013; 123(6):2629-42. PMC: 3668817. DOI: 10.1172/JCI64704. View

18.

Hansen S, Vieville C, Whizin N, Coyne-Johnson L, Siess D, Drummond D . Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med. 2009; 15(3):293-9. PMC: 2720091. DOI: 10.1038/nm.1935. View

19.

Hansen S, Ford J, Lewis M, Ventura A, Hughes C, Coyne-Johnson L . Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011; 473(7348):523-7. PMC: 3102768. DOI: 10.1038/nature10003. View

20.

Vasan S, Schlesinger S, Huang Y, Hurley A, Lombardo A, Chen Z . Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One. 2010; 5(1):e8617. PMC: 2799527. DOI: 10.1371/journal.pone.0008617. View